HUTCHMED Reports P-III Trial (ESLIM-01) Results of Sovleplenib for Primary Immune Thrombocytopenia in China
Shots:
- The P-III trial evaluating sovleplenib, a selective, oral inhibitor targeting spleen tyrosine kinase vs PBO in 188 adult patients with primary ITP who have received one prior line of standard therapy
- The trial met its 1EPs & showed a statistically significant increase in durable response rate while the 2EPs incl. response rate and safety were also met. The results will be submitted at an upcoming scientific conference
- The company plans to submit the NDA around the end of 2023. Sovleplenib received the BTD from the NMPA in Jan 2022 while P-I/II study results were published in The Lancet Haematology showed a rapid and durable increase in platelet counts in previously treated patients with ITP
Ref: HUTCHMED | Image: HUTCHMED
Related News:- HUTCHMED Receives the NMPA’s Breakthrough Therapy Designation for Fruquintinib + Sintilimab to Treat Advanced Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
